biostudies-literatureWescott ECU.S. Department of Defense (DOD)NCI NIH HHSHHS | NIH | National Cancer Institute (NCI)1120-1134https://www.ebi.ac.uk/biostudies/studies/S-EPMC11041871biostudies-literatureUnknown4(4)Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 family ligand with proposed immunosuppressive functions being explored as a cancer immunotherapy target and may be associated with anti-PD-L1 resistance. However, little is known about its regulation and effect on immune cell function in breast cancers. We assessed murine and human breast cancer cells to identify regulation mechanisms of B7-H4 in vitro. We used an immunocompetent anti-PD-L1-sensitive orthotopic mammary cancer model and induced ectopic expression of B7-H4. We assessed therapy response and transcriptional changes at baseline and under treatmentCancer research communicationsEpithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.PMC110418715P30CA068485P01 CA210961BC1700375P50CA098131Hanna ABronzini JWulfkuhle JWescott ECTaylor BCDees ECOpalenik SREsserman LJIsaacs CSanchez VWilson JTBallinger TJBharti VSanta-Maria CAShah PDPetricoin EFBalko JMvan ˈt Veer LJHirst GLBrown Swigart LPietenpol JALehmann BDSun XAbramson VGSanders MEGallagher RIGomez HGonzalez-Ericsson PfalseEpithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and chemotherapy have been FDA approved for metastatic and early-stage triple-negative breast cancer (TNBC), but most patients do not benefit. B7-H4 is a B7 family ligand with proposed immunosuppressive functions being explored as a cancer immunotherapy target and may be associated with anti-PD-L1 resistance. However, little is known about its regulation and effect on immune cell function in breast cancers. We assessed murine and human breast cancer cells to identify regulation mechanisms of B7-H4 in vitro. We used an immunocompetent anti-PD-L1-sensitive orthotopic mammary cancer model and induced ectopic expression of B7-H4. We assessed therapy response and transcriptional changes at baseline and under treatment2024-01-01T00:00:00Z2024 Apr2026-05-29T12:38:47.411Z2026-04-08T04:47:55.508ZS-EPMC110418713868724710.1158/2767-9764.CRC-23-0468